Glaukos Corp (GKOS) — Quality & forensics
As of 2026-09-24 — refreshed nightly. Closelook readings from an investment research diary, not ratings or advice.
The Closelook module scores
- Valuation 18
- Quality 23
- Growth 88
- Balance sheet 62
- Cash quality 48
- Capital allocation 10
- Momentum 73
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the GKOS chart & overview · the earnings record
FAQ · from the current data · as of 2026-09-24
Quick answers
What is Glaukos Corp's Closelook quality reading?
The composite reads 47/100 across 7 modules, as of 2026-09-24: valuation 18, quality 23, growth 88, balance sheet 62, cash quality 48, capital allocation 10, momentum 73. Closelook scores are research diary readings, not ratings or investment advice.
What is Glaukos Corp's Altman Z-Score?
22.17, which sits in the safe zone (above 2.99) as of 2026-09-24. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Glaukos Corp's Piotroski F-Score?
3 of 8, as of 2026-09-24. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Glaukos Corp's Beneish M-Score indicate?
-2.62 — below the −1.78 manipulation-risk threshold, as of 2026-09-24. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelook universe
then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- DXCM DexCom Incindustry
- GMED Globus Medicalindustry
- SECT-B.ST Sectra AB (publ)industry
- CEVI.ST CellaVision ABindustry
- SOON.SW Sonova H Agindustry
- SYK Stryker Corporationindustry
- TXG 10X Genomics Incindustry
- BRKR Bruker Corporationindustry
- BIO Bio-Rad Laboratories Incindustry
- CERS Cerus Corporationindustry
- EW Edwards Lifesciences Corpindustry
- NVCR Novocure Ltdindustry
- IART Integra LifeSciences Holdingsindustry
- PACB Pacific Biosciences of Californiaindustry
- PEN Penumbra Incindustry
- MDT Medtronic PLCindustry
- SHL.DE Siemens Healthineers AGindustry
- BSX Boston Scientific Corpindustry
- ABT Abbott Laboratoriesindustry
- PHG Koninklijke Philips NV ADRindustry